Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Short answer: Johnson & Johnson’s 64 consecutive years of dividend increases are evidence of a durable shareholder-return culture, not a stand-alone buy signal. The shares offered a 2.03% indicated yield and traded at 30.57 times trailing earnings at the October 12, 2026 close. That valuation can work if the company delivers the growth in its updated 2026 outlook and keeps its major legal, patent, clinical and product-safety risks contained; it leaves less room for disappointment than a distressed valuation would.
This is a decision framework rather than individualized financial advice. The relevant question is not simply whether JNJ is a “good dividend stock,” but whether its expected growth, cash generation and resilience justify the price for your required return and risk tolerance.
As an Amazon Associate I earn from qualifying purchases.
What J&J’s “dividend royalty” status actually tells you
Johnson & Johnson announced a 3.1% increase in its quarterly dividend on April 14, 2026, extending its record to 64 consecutive years of annual increases. That is an unusually long operating history across recessions, changing interest rates and multiple product cycles. It demonstrates that management has historically treated a rising dividend as a priority.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallThe record is backward-looking, however. It cannot guarantee another increase, preserve your purchasing power if inflation exceeds dividend growth, or prove that the stock is fairly valued today. A company can maintain a streak while raising its dividend slowly, and a high-quality business can still produce a poor investment return when bought at an excessive price.
#1 Best Overall
The latest declared payment
J&J’s Q3 2026 dividend declaration set the payment at $1.34 per share each quarter, payable September 8, 2026. Multiplying that quarterly amount by four gives a simple annualized dividend of $5.36 per share. The annualized figure is consistent with the market-data snapshot used for the October valuation discussion below.
Annualizing a quarterly payment assumes the rate remains unchanged for four payments. It is not a promise that the next declaration will be identical, and it does not account for taxes or changes in your number of shares.
Dividend and market snapshot at the October 12 close
The following figures come from the cited market-data snapshot at the October 12, 2026 close. They can change every trading day as the share price, earnings estimates and dividend declarations change.
| Measure | Reported figure | How to interpret it |
|---|---|---|
| Closing share price | $263.73 | One-day market price at the October 12, 2026 close |
| Annualized dividend | $5.36 per share | Based on the $1.34 quarterly declaration |
| Indicated dividend yield | 2.03% | Annualized dividend divided by that share price; moves with the price |
| Trailing P/E | 30.57 | Price divided by the vendor’s trailing earnings measure |
| Forward P/E | 24.01 | Price divided by the vendor’s forward earnings estimate |
A 2.03% yield is primarily an income-and-growth proposition, not a high-current-income strategy. Your return would need to come from the dividend plus future earnings growth and any change in the valuation multiple. The two P/E figures are market-data ratios, not an intrinsic-value calculation. They do not by themselves establish that JNJ is cheap or expensive.
Is the underlying business still growing?
2025 results provide the starting point
For full-year 2025, J&J reported $94.193 billion in sales, $11.03 in reported (GAAP) earnings per share and $10.79 in adjusted EPS. Reported and adjusted earnings are not interchangeable: adjusted EPS excludes certain items, while GAAP earnings include the accounting effects that actually flow through the company’s reported results.
Management raised its 2026 outlook after Q2
In January 2026, management initially guided to 2026 reported sales of $100.5 billion and adjusted EPS of $11.53. Following the second quarter, it raised that outlook to $101.1 billion in sales and $11.68 in adjusted EPS. The second quarter itself produced $25.3 billion of sales, up 6.6% from the comparable period. MedTech operational sales grew 3.6% in the quarter.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Guidance is management’s estimate, not a contractual commitment. It can change with exchange rates, launches, demand, trial results, legal developments and acquisitions. Because the updated EPS figure is adjusted, it should not be used as though it were a forecast of GAAP EPS.
Where growth is coming from—and what is offsetting it
J&J said Innovative Medicine growth was led by DARZALEX, CARVYKTI, TECVAYLI and the RYBREVANT/LAZCLUZE combination. STELARA’s decline partly offset those gains. The company’s stated growth focus spans Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. That breadth can reduce dependence on one product, but it does not eliminate the need for successful launches and replacement revenue when older medicines lose exclusivity.
Chief Executive Officer Joaquin Duato called 2025 “a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history.” That is management’s characterization, not an independent assessment; investors should test it against future sales, margins, cash flow and pipeline execution.
How to judge whether the dividend is sustainable
Look beyond the streak
A sustainable dividend normally requires recurring free cash flow, manageable debt and a payout that leaves room for research, capital spending, acquisitions and legal obligations. The available figures do not provide a complete current payout-ratio calculation, so it would be misleading to infer one from the dividend streak alone.
J&J’s investor-relations page says more than 65% of five-year free cash flow was returned to shareholders. This is a company-wide shareholder-return metric, not a dividend payout ratio. “Returned to shareholders” can include share repurchases as well as dividends; it does not mean that more than 65% of free cash flow funded the dividend.
Recommended Free Tools
Use a cash-flow checklist
- Compare dividends with multi-year free cash flow, not a single quarter.
- Check whether free cash flow remains after research, manufacturing, capital spending and legal payments.
- Separate dividend growth from buybacks when evaluating total shareholder returns.
- Watch debt, refinancing needs and major acquisition commitments.
- Confirm that future increases are supported by operating growth rather than a rising payout burden.
The 64-year record is a useful prior belief about management’s priorities. It is not a substitute for checking the latest cash-flow statement and balance-sheet disclosures.
Risks that can weaken the buy case
Patent expiry and competition
Patent challenges and expirations can reduce sales of successful medicines. Competitors can also introduce therapies, devices or procedures that make an established product less attractive. The fact that several newer medicines are growing does not guarantee they will replace every dollar lost from products such as STELARA.
Clinical and regulatory uncertainty
Drug and device candidates can fail trials, show safety or efficacy problems, face delays or fail to receive regulatory approval. Even an approved product can encounter new evidence that changes its use, labeling or reimbursement. These outcomes can reduce expected revenue and increase development costs.
Product safety, manufacturing and supply
Product-quality or safety concerns can lead to recalls, restrictions, remediation expenses and reputational damage. Manufacturing interruptions and supply-chain problems can delay shipments or raise costs. These risks affect both Innovative Medicine and MedTech, although their operational manifestations differ.
Litigation and government action
J&J identifies significant litigation and government action as material risks. Legal costs, settlements, judgments or changes in government policy can reduce cash available for dividends and investment. The company also said it cannot provide forward GAAP financial measures when uncertain legal outcomes, unusual gains and losses, acquisition expenses and purchase-accounting adjustments cannot be predicted with reasonable certainty without unreasonable effort.
A long streak cannot insulate shareholders from a sudden decline in cash generation caused by any of these events.
Does the October valuation leave enough room for error?
At $263.73, the stock’s 30.57 trailing P/E is materially higher than its 24.01 forward P/E because the latter uses expected future earnings. That gap implies the market-data vendor expects earnings to grow, but it does not tell you whether the estimate will be met or whether the multiple will remain unchanged.
Rank #4
Use the valuation as a set of questions:
- What annual earnings and free-cash-flow growth do you require to meet your target return?
- How much of that return must come from dividends versus price appreciation?
- Would you still hold the shares if the P/E contracted while earnings grew?
- How would a patent setback, litigation charge or failed launch affect your estimate?
- Is a 2.03% starting yield adequate compensation for those uncertainties?
Do not treat the quoted P/E as a target price. A proper intrinsic-value analysis would require assumptions about future cash flows, discount rates, terminal growth and scenario probabilities that are not established by this snapshot.
A practical decision process for prospective buyers
1. Define the job the stock must perform
If you need substantial current income, a 2.03% indicated yield may not meet your objective. If you seek a combination of moderate income, potential dividend growth and exposure to a diversified healthcare company, the profile may be more relevant.
2. Set a required return and downside tolerance
Write down the return you need after inflation, taxes and fees. Then decide how much decline you could tolerate if litigation, a patent loss or a market-wide repricing reduced the share price.
3. Verify the numbers at the time you invest
Recheck the latest declared dividend, share price, trailing and forward earnings, free cash flow, debt and management guidance. The October 12 figures are a historical snapshot, not a live quote.
4. Test the growth thesis
Track whether the products identified as growth drivers continue to offset STELARA’s decline and other losses of exclusivity. Compare actual sales and adjusted EPS with the $101.1 billion sales and $11.68 adjusted-EPS guidance, while keeping GAAP results separate.
Free tools Windows power users keep installed
One-click scans. No signup required.
5. Compare alternatives on consistent axes
If you compare JNJ with other dividend stocks, use the same measures for every company:
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
- Current yield and the history and pace of dividend growth
- Dividend coverage by recurring free cash flow
- Expected earnings and cash-flow growth
- Valuation under conservative and optimistic assumptions
- Balance-sheet capacity and refinancing risk
- Business concentration, patent exposure and litigation risk
- Total-return potential, not yield alone
No peer comparison is established here, so a claim that JNJ is better or worse than a named alternative would require additional, consistent data.
6. Choose a purchase approach
An investor who is comfortable with the business but uncertain about valuation can use a staged purchase plan rather than committing the entire intended position at once. That reduces timing risk but does not remove business risk or guarantee a lower average cost. A one-time purchase is simpler and may perform better if the stock rises, but it accepts the current valuation immediately.
What to monitor after buying
- Dividend declarations and the annual increase percentage
- Operating sales in Innovative Medicine and MedTech
- Progress of the oncology and immunology products cited by management
- STELARA erosion and the effect of patent expirations
- GAAP earnings, adjusted EPS and the reconciliation between them
- Free cash flow after capital spending and legal payments
- Material litigation, regulatory decisions, recalls and supply interruptions
- Changes to 2026 guidance and subsequent-year outlooks
The supplied information includes the Q3 2026 dividend declaration but not Q3 2026 operating results. The search information identified October 13 as the Q3 earnings date; those results should be reviewed separately before relying on an updated earnings or valuation thesis.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsVerdict: is JNJ a buy because of its dividend record?
The dividend streak strengthens the quality case but does not settle the purchase decision. J&J had a 64-year history of annual increases, a $1.34 quarterly dividend and an updated 2026 outlook showing 6.6% second-quarter sales growth and guidance for $101.1 billion of sales and $11.68 of adjusted EPS. Against that, the October 12 snapshot showed a 2.03% yield and 30.57 trailing P/E, while patent, competition, clinical, regulatory, product-safety, supply-chain and litigation risks remain real.
For an investor who values a diversified healthcare business, can accept a modest starting yield and believes earnings and cash flow can compound beyond the current expectations, JNJ may merit further work or a measured position. For someone seeking high current income, a wide margin of safety or minimal exposure to product and litigation risk, the same dividend record is not enough. The buy decision should follow your required return, valuation discipline and ability to withstand the risks—not the number of years on the dividend calendar.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
